Physician profile
Robert S Staton
NPI 1629270442
$4,409.68
in general payments reported to CMS, 2019-2025
30 companies · $998 in 2025
The $998 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $145 · 2021: $489 · 2022: $701 · 2023: $857 · 2024: $683 · 2025: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,538.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,127.48 | 2019-2025 | Trintellix |
| Abbvie INC. | $761.31 | 2021-2024 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $329.59 | 2022-2025 | Caplyta |
| Bausch Health US, LLC | $227.41 | 2019-2025 | Wellbutrin, Aplenzin |
| Janssen Pharmaceuticals, INC | $212.05 | 2019-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $176.39 | 2020-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $161.06 | 2023-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $133.80 | 2022-2024 | Qelbree, Qelbree |
| Alkermes, INC. | $129.34 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $128.96 | 2019-2025 | Austedo Xr |
| Validus Pharmaceuticals LLC | $115.91 | 2022-2023 | Equetro |
| Tris Pharma INC | $79.99 | 2022-2023 | Dyanavel Xr |
| Allergan, INC. | $79.11 | 2019-2020 | |
| Adlon Therapeutics L.P. | $78.09 | 2019-2021 | |
| Axsome Therapeutics, INC. | $76.83 | 2023-2025 | Auvelity |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $69.01 | 2022-2024 | Quviviq |
| Eisai INC. | $57.86 | 2021 | |
| Noven Therapeutics, LLC | $56.22 | 2023 | Secuado |
| Almatica Pharma LLC | $54.20 | 2021-2024 | Loreev Xr |
| Corium, LLC | $49.16 | 2021-2025 | Azstarys |
| Shire North American Group INC | $45.81 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $43.69 | 2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $42.51 | 2020-2022 | |
| Boston Scientific Corporation | $34.43 | 2019 | |
| Alfasigma USA, INC. | $34.41 | 2022 | |
| Avanir Pharmaceuticals, INC. | $32.30 | 2022 | |
| Jazz Pharmaceuticals INC. | $21.55 | 2019 | |
| Arbor Pharmaceuticals, INC. | $19.34 | 2019 | |
| Tempus Ai, INC | $18.54 | 2024 | |
| Sunovion Pharmaceuticals INC. | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Staton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.